Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.
The major pathologic beta(1)-adrenergic receptor (beta(1)-AR) subtype in heart failure is beta(1)-AR. The authors' laboratory has thus pursued genetic variation of the beta(1)-AR gene at the molecular, cellular, physiologic, and clinical levels as the potential basis for interindividual variability in the response to beta-blocker treatment during heart failure. This article reviews these findings, with emphasis on mechanism of action and future directions.
Liggett
Stephen B
SB
Cardiopulmonary Genomics Program, University of Maryland School of Medicine, 20 Penn Street, HSF-II, Baltimore, MD, USA. sligg001@umaryland.edu
D000262:Adenylyl Cyclases; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D009206:Myocardium; D010641:Phenotype; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics*; D015398:Signal Transduction
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D018342:Receptors, Adrenergic, beta-1; D000262:Adenylyl Cyclases